Trial reportScientific reports2021
Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- The association between neurofilament light chain and cognitive function: a UK Biobank cohort study.Journal of neurology · 2026Article
- Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men.Molecular psychiatry · 2025Article
- The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort.The journal of prevention of Alzheimer's disease · 2025Article
- Plasma homocysteine level and trajectories in association with longitudinal increase in plasma neurofilament light among urban adults.GeroScience · 2025Article
- Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Evaluating the safety and feasibility of remote ischemic conditioning for slowing cognitive decline in mild Alzheimer's dementia.Frontiers in neurology · 2025Article
- Emerging Trends: Neurofilament Biomarkers in Precision Neurology.Neurochemical research · 2024Review
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Plasma markers of neurodegeneration, latent cognitive abilities and physical activity in healthy aging.Scientific reports · 2024Article
- Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults.European journal of epidemiology · 2024Article
- Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.EBioMedicine · 2024Article
- Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.Neurology · 2024Article
- Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men.Alzheimer's research & therapy · 2024Article
- Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study.GeroScience · 2024Article
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
- Serum neurofilament light chain and cognition decline in US elderly: A cross-sectional study.Annals of clinical and translational neurology · 2024Article
- Association of frailty and serum neurofilament light chain levels: the mediating role of estimated glomerular filtration rate.Frontiers in aging neuroscience · 2024Article
- Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study.Neurology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 14 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofilament light chain (NfL) has been associated with cognitive status in multiple neurodegenerative conditions. Studies about plasma NfL and cognitive decline in older adults are still limited. 504 older adults (median age 75 years) who expressed memory complaints were selected from the Multidomain Alzheimer's Preventive Trial (MAPT) and were classified as normal cognition (NC) or mild cognitive impairment (MCI). Cognitive functions were measured as mini mental state examination (MMSE) and composite cognitive score (CCS) over a 4-year period. Plasma NfL was measured at the first or the second year of the MAPT. Mixed-effects linear models were performed to evaluate cross-sectional and longitudinal associations. In the whole population, higher plasma NfL was cross-sectionally associated with lower cognitive functions (MMSE: β = - 0.007, 95% CI [- 0.013, - 0.001]; CCS: β = - 0.003, 95% CI [- 0.006, - 0.001]). In adults with MCI, but not NC, higher plasma NfL was associated with lower CCS at the cross-sectional level (β = - 0.003, 95% CI [- 0.005, - 0.0002]). The upper quartile NfL group further demonstrated more over time decline in CCS (β = - 0.07, 95% CI [- 0.12, - 0.01]) under the MCI status. Plasma NfL can be a promising biomarker of progressive cognition decline in older adults with MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.